Padsevonil in ARISE Phase IIb trial does not meet statistical significance for treatment of focal-onset seizures . UCB
UCB, a global biopharmaceutical company, announced top-line results from ARISE (NCT03373383), the first of two adequate and well-controlled studies, investigating the efficacy and safety of padsevonil for the… read more.